Clinical Trials on Splanchnic Vein Thrombosis in Czechia

Total 135 results

Population Health Research Institute
Bristol-Myers Squibb; Pfizer; Canadian Institutes of Health Research (CIHR); Me...

Completed

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)

Stroke | Atrial Fibrillation

United States, Spain, Canada, Belgium, United Kingdom, Denmark, Germany, Switzerland, Netherlands, Hungary, Norway, Czechia, Italy
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Boehringer Ingelheim

Completed

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Venous Thromboembolism

United States, Korea, Republic of, Lebanon, Czechia, Saudi Arabia, Bulgaria, Serbia, Thailand, Greece, Malaysia, Vietnam, Belgium, Canada, United Kingdom, Turkey, Germany, Italy, Hungary, Latvia, Portugal, Russian Federation, Neth... and more
Sanofi

Completed

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

Pulmonary Embolism

United Kingdom, United States, Canada, Argentina, Austria, Norway, Czech Republic, Denmark, France, Australia, Belgium, Brazil, Finland, Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland
Sanofi

Completed

PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)

Acute Ischemic Stroke

Korea, Republic of, Italy, Brazil, Canada, Colombia, Israel, Mexico, Poland, Czech Republic, United States, Australia, Austria, India, South Africa, Turkey
UCB Biopharma SRL
Parexel

Completed

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Thrombocytopenia

Australia, Bulgaria, Czechia, Georgia, Germany, Italy, Moldova, Republic of, Poland, Romania, Spain, United Kingdom
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pulmonary Embolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Switzerland, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Estonia, Thailand, Brazil, Germany, Korea, Republic... and more
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, United States, Argentina, Australia, United Kingdom, Poland
Rigel Pharmaceuticals

Completed

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)

Immune Thrombocytopenic Purpura

Spain, Norway, Poland, Czechia, Germany, United States, Austria, Bulgaria, Romania
Ilkos Therapeutic Inc.

Completed

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

Venous Leg Ulcer

Spain, Hungary, Canada, United States, Brazil, Argentina, Austria, Czechia, Italy, Poland, Slovakia
Daiichi Sankyo, Inc.
The TIMI Study Group

Completed

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48)

Stroke | Embolism | Atrial Fibrillation

United States, Australia, France, Italy, Poland, Taiwan, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Romania, Russian Federation, Serbia, South Africa, Turkey, Korea, Republic of and more
Molnlycke Health Care AB

Completed

Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers

Venous Leg Ulcers | Mixed Leg Ulcers

France, Germany, Netherlands, Czech Republic
Sanofi

Terminated

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (BOREALIS-AF)

Atrial Fibrillation

South Africa, Thailand, Chile, Guatemala, Ukraine, United States, Argentina, Australia, Austria, Belarus, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Greece, India, ... and more
Swedish Orphan Biovitrum

Active, not recruiting

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP (ADOPT)

Immune Thrombocytopenia | ITP

Croatia, Czechia, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Pfizer

Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

United States, Australia, Canada, Czechia, Poland, Hungary, United Kingdom
Principia Biopharma, a Sanofi Company

Active, not recruiting

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Immune Thrombocytopenic Purpura

United States, Australia, Bulgaria, Canada, Czechia, Netherlands, Norway, United Kingdom
Healthpoint

Terminated

Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

Ulcer | Venous Ulcer | Venous Stasis Ulcer

Germany, Poland, Belgium, Czech Republic, Hungary
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Terminated

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (NAVIGATE ESUS)

Stroke

Denmark, France, Spain, China, United States, Switzerland, Germany, Greece, Korea, Republic of, Portugal, Japan, Israel, Canada, Australia, Turkey, Russian Federation, Sweden, Austria, Czechia, Poland, United Kingdom, Belgium, Brazil, Hungar... and more
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Stroke | Embolism | Atrial Fibrillation

United States, Australia, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Colombia, Israel, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic... and more
Daiichi Sankyo, Inc.

Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke (ASSENT)

Acute Ischemic Stroke | Thrombotic Disease

United States, Korea, Republic of, Taiwan, Australia, Spain, France, United Kingdom, Germany, Czechia, Italy, Slovakia
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
Rigel Pharmaceuticals

Completed

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

Spain, United States, Australia, Poland, United Kingdom, Canada, Czechia, Bulgaria, Romania, Austria, Denmark, Hungary, Italy, Netherlands, Norway
Bayer

Terminated

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF)

Atrial Fibrillation | Prevention of Stroke or Systemic Embolism

Canada, United States, Israel, Korea, Republic of, China, Taiwan, Belgium, Australia, Singapore, Malaysia, Slovakia, United Kingdom, Czechia, Latvia, Japan, Brazil, Lithuania, Germany, France, Sweden, Turkey, Switzerland, Estonia, Bul... and more
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (VAYHIT2)

Primary Immune Thrombocytopenia

United States, China, Germany, Spain, Singapore, Japan, Taiwan, Belgium, Italy, Czechia, Hungary, Malaysia, Korea, Republic of, Turkey, Argentina, Thailand, India, United Kingdom, France, Australia, Romania, Austria, Norway, Netherlands, Philippin...
Amgen

Completed

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States, Canada, Belgium, Czechia, Mexico, Turkey, Australia, Spain, France, Israel, Hungary, South Africa, Poland, Russian Federation, United Kingdom, Brazil, Switzerland
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)

Atypical Hemolytic Uremic Syndrome

China, Korea, Republic of, Austria, Taiwan, Greece, Czechia, United States, Japan, Brazil, United Kingdom, India, Slovakia, Slovenia
GlaxoSmithKline

Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (PETIT2)

Idiopathic Thrombocytopenic Purpura

Thailand, Israel, Poland, Russian Federation, Spain, Germany, United Kingdom, Taiwan, Hong Kong, Czech Republic, Italy, United States, Argentina
Bayer

Completed

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (CONVERT)

Hemodialysis | End-stage Renal Disease | Hemodiafiltration | Prevention of Thromboembolic Events

Spain, Greece, Belgium, Russian Federation, Netherlands, Turkey, Japan, Australia, Austria, Bulgaria, Italy, Ukraine, Czechia, Israel, United States, Hungary, Lithuania, Poland, Portugal
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more

Clinical Trials on Splanchnic Vein Thrombosis in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations